Art. -Nr.: HY-13997

Ombitasvir

Name: Ombitasvir
Brand: MedChemExpress
SKU: HY-13997
Price: 90.00 USD
Availability: InStock
Rating: 5 (9 reviews)

(Synonyms: ABT-267)

9 Cited Publications

Kundenbewertung

Based on 9 publication(s) in Google Scholar

Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC₅₀s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 98.62%
CAS. Nr.: 1258226-87-7
Formel: C₅₀H₆₇N₇O₈
Molecular Weight:894.11

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Ombitasvir Chemical Structure

CAS. Nr.: 1258226-87-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (9)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC₅₀s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.

IC₅₀ & Target

EC50: 0.82 to 19.3 pM (HCV genotypes 1 to 5), 366 pM (HCV genotype 6a)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-7	CC₅₀	>1 nM Compound: Ombitasvir	Cytotoxicity against human HuH7 replicon cells after 3 days by CellTiter-Fluor assay Cytotoxicity against human HuH7 replicon cells after 3 days by CellTiter-Fluor assay	[PMID: 29454920]
Huh-7	EC₅₀	0.005 nM Compound: 38, ABT-267	Antiviral activity against HCV1b Con1 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay Antiviral activity against HCV1b Con1 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay	[PMID: 24400777]
Huh-7	EC₅₀	0.014 nM Compound: 38, ABT-267	Antiviral activity against HCV1a H77 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay Antiviral activity against HCV1a H77 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay	[PMID: 24400777]
Huh-7	EC₅₀	0.056 nM Compound: 38, ABT-267	Antiviral activity against HCV1b Con1 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay in presence of 40% human plasma Antiviral activity against HCV1b Con1 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay in presence of 40% human plasma	[PMID: 24400777]
Huh-7	EC₅₀	0.186 nM Compound: 38, ABT-267	Antiviral activity against HCV1a H77 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay in presence of 40% human plasma Antiviral activity against HCV1a H77 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay in presence of 40% human plasma	[PMID: 24400777]
Huh-7	EC₅₀	1.71 pM Compound: 38, ABT-267	Antiviral activity against HCV4a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay Antiviral activity against HCV4a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay	[PMID: 24400777]
Huh-7	EC₅₀	12.4 pM Compound: 38, ABT-267	Antiviral activity against HCV2a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay Antiviral activity against HCV2a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay	[PMID: 24400777]
Huh-7	EC₅₀	19.3 pM Compound: 38, ABT-267	Antiviral activity against HCV3a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay Antiviral activity against HCV3a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay	[PMID: 24400777]
Huh-7	EC₅₀	4.3 pM Compound: 38, ABT-267	Antiviral activity against HCV2b infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay Antiviral activity against HCV2b infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay	[PMID: 24400777]
Huh-7	EC₅₀	4.3 pM Compound: 38, ABT-267	Antiviral activity against HCV5a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay Antiviral activity against HCV5a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay	[PMID: 24400777]
Huh-7	EC₅₀	415 pM Compound: 38, ABT-267	Antiviral activity against HCV6a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay Antiviral activity against HCV6a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay	[PMID: 24400777]

In Vitro

Ombitasvir is active against the genotype 2a JFH-1 replicon, with an EC₅₀ of 0.82 pM, and the EC₅₀s of ombitasvir are 42 pM and 68 pM against the L28 and F28 variants of this genotype 6a replicon, respectively^[1]. In GT1a, variants M28V, L31V, and H58D confers 58- to 243-fold resistance to Ombitasvir. Single variants M28T, Q30R, and Y93C/S confers 800- to 8965-fold resistance, while Y93H/N confers >40000-fold resistance to Ombitasvir^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1258226-87-7
Appearance Solid
Molecular Weight 894.11
Formel C₅₀H₆₇N₇O₈
Color White to light yellow
SMILES

CC(C)(C)C(C=C1)=CC=C1N2[C@H](C3=CC=C(NC([C@H]4N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC4)=O)C=C3)CC[C@H]2C5=CC=C(NC([C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O)=O)C=C5
Synonyms

ABT-267
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (9)

All

Sort by:

Journal Impact Factor

Int J Mol Sci

Discovery of TRPV4-Targeting Small Molecules with Anti-Influenza Effects Through Machine Learning and Experimental Validation. [Abstract]

2025 Feb 6;26(3):1381. PMID: 39941149
Antiviral Res

A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. [Abstract]

2017 Mar:139:18-24. PMID: 28025084
J Virol

Characterization of Recombinant Flaviviridae Viruses Possessing a Small Reporter Tag. [Abstract]

2018 Jan 2;92(2):e01582-17. PMID: 29093094
Xenobiotica

Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro. [Abstract]

2019 Aug;49(8):935-944. PMID: 30227770
J Liq ChromaTogr R T

2019: 1-9.
University of Glasgow

2024 Mar.
SSRN

2024 Jan 26.
Chemrxiv

2021, Jun 10.
Chem Cent J

Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD. [Abstract]

2017 Jan 3:11:1. PMID: 28101128

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 33 mg/mL (36.91 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1184 mL

5.5922 mL

11.1843 mL

5 mM

0.2237 mL

1.1184 mL

2.2369 mL

10 mM

0.1118 mL

0.5592 mL

1.1184 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Krishnan P, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015 Feb;59(2):979-87 [Content Brief]

[2]. DeGoey DA, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.1184 mL	5.5922 mL	11.1843 mL	27.9608 mL
	5 mM	0.2237 mL	1.1184 mL	2.2369 mL	5.5922 mL
	10 mM	0.1118 mL	0.5592 mL	1.1184 mL	2.7961 mL
	15 mM	0.0746 mL	0.3728 mL	0.7456 mL	1.8641 mL
	20 mM	0.0559 mL	0.2796 mL	0.5592 mL	1.3980 mL
	25 mM	0.0447 mL	0.2237 mL	0.4474 mL	1.1184 mL
	30 mM	0.0373 mL	0.1864 mL	0.3728 mL	0.9320 mL

Bioz

Keywords

Ombitasvir

9 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ombitasvir

Publications Citing Use of MedChemExpress (MCE) Ombitasvir